MYRIAD GENETICS, INC. MYGN Income Statement

Myriad genetics, inc. (MYGN)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09
Total revenue
164,000	195,100	186,300	215,400	216,600	216,800	202,300	193,900	183,100	187,900	178,800	199,600	194,700	196,700	177,500	173,200	190,500	193,300	183,500	189,900	180,000	184,400	168,800	188,749	182,924	204,060	202,467	174,151	156,472	149,140	133,437	132,965	129,777	122,811	110,452	107,412	102,374	100,440	91,858	93,928	90,830	92,768	85,122
Costs and expenses:
Research and development expense
19,700	18,800	21,300	20,900	21,500	22,400	21,100	17,700	18,500	16,800	17,800	18,800	17,600	18,600	19,400	19,500	17,200	16,700	17,200	18,700	16,700	17,500	22,600	20,210	13,397	17,090	16,803	14,575	13,618	14,107	11,400	12,144	11,753	10,243	8,505	9,230	6,667	6,092	5,762	5,253	5,885	5,059	5,676
Change in the fair value of contingent consideration
-3,400	-100	700	-300	0	1,000	400	200	-1,200	13,000	-73,200	-2,700	5,200	-3,800	500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling, general, and administrative expense
132,900	135,600	135,500	149,800	140,600	135,200	129,900	112,500	107,900	107,400	107,200	122,100	122,100	120,300	111,900	91,400	90,500	90,800	86,500	96,600	91,300	92,700	85,400	84,350	87,631	77,840	77,279	71,507	64,602	59,563	56,128	56,583	54,700	50,986	46,114	43,881	42,750	43,716	39,494	39,798	40,840	42,104	38,672
Goodwill and intangible asset impairment charges
98,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total costs and expenses
297,700	203,900	207,200	221,000	210,700	210,700	201,100	176,100	169,300	181,600	94,800	180,700	189,200	179,500	171,800	150,900	147,900	148,100	140,200	153,600	144,300	148,100	142,900	135,539	127,637	121,061	119,563	108,237	98,554	93,554	84,855	85,680	83,681	77,346	68,980	65,635	60,550	61,854	56,267	56,312	57,605	58,246	55,410
Operating income (loss)
-133,700	-8,800	-20,900	-5,600	5,900	6,100	1,200	17,800	13,800	6,300	84,000	18,900	5,500	17,200	5,700	22,300	42,600	45,200	43,300	36,300	35,700	36,300	25,900	53,210	55,287	82,999	82,904	65,914	57,918	55,586	48,582	47,285	46,096	45,465	41,472	41,777	41,824	38,586	35,591	37,616	33,225	34,522	29,712
Other income (expense):
Interest income
800	800	900	900	700	900	700	500	500	400	400	300	300	300	300	400	300	100	100	100	100	100	100	210	2,498	1,330	1,362	1,313	1,434	1,385	1,368	1,395	1,379	1,382	473	410	547	548	721	984	1,232	1,531	1,913
Interest expense
2,300	2,500	2,900	3,200	3,200	3,400	2,200	1,100	500	700	900	1,200	1,500	2,600	700	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-128	-	6	-64	-140	-80	-59	-80	-134	193	-23	-286	215
Other
4,100	-900	600	200	-100	0	1,100	800	-500	-400	-300	-100	1,500	-2,600	-1,300	1,900	200	-200	100	-800	-300	1,500	-100	-934	-442	-185	-439	-1,343	-111	14	1,240	-	-	-	-	-	-	-	-	-	1,255	1,817	1,698
Total other income (expense):
2,600	-2,600	-1,400	-2,100	-2,600	-2,500	-400	200	-500	-700	-800	-1,000	300	-4,900	-1,700	2,100	500	-200	200	-	-200	1,600	-	-724	2,056	1,145	923	-	1,323	1,399	-	1,186	1,385	1,318	333	-	488	468	587	-	-	-	-
Income (loss) before income tax
-131,100	-11,400	-22,300	-7,700	3,300	3,600	800	18,000	13,300	5,600	83,200	17,900	5,800	12,300	4,000	24,400	43,100	45,000	43,500	35,600	35,500	37,900	25,900	52,486	57,343	84,144	83,827	67,252	59,241	56,985	49,822	48,471	47,481	46,783	41,805	42,107	42,312	39,054	36,178	38,605	34,480	36,339	31,410
Income tax provision (benefit)
-15,900	-3,100	-1,700	-3,400	-3,600	1,000	1,600	3,500	4,300	-25,300	4,500	5,800	3,000	6,200	5,200	9,100	8,600	7,900	13,200	16,800	14,100	13,900	9,900	18,881	20,573	33,784	28,362	23,116	21,349	21,949	19,686	19,330	17,866	18,487	16,706	16,066	14,372	14,863	13,640	-14,646	1,229	980	968
Net income (loss)
-115,200	-8,300	-20,600	-4,300	6,900	2,600	-800	14,500	9,000	30,900	78,700	12,100	2,800	6,100	-1,200	15,300	34,500	37,100	30,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to non-controlling interest
-	-	-	-100	0	0	-100	0	-100	0	-100	-200	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) attributable to Myriad Genetics, Inc. stockholders
-115,200	-8,300	-20,600	-4,200	6,900	2,600	-700	14,500	9,100	30,900	78,800	12,300	2,800	6,100	-1,200	15,300	34,500	37,100	30,300	18,800	21,400	24,000	16,000	33,605	36,770	50,360	55,465	44,136	37,892	35,036	30,136	29,141	29,615	28,296	25,099	26,041	27,940	24,191	22,538	53,251	33,251	35,359	30,442
Earnings (loss) per share:
Basic
-1.55	-0.11	-0.28	-0.06	0.09	0.04	-0.01	0.21	0.13	0.45	1.15	0.18	0.04	0.09	-0.02	0.21	0.49	0.53	0.44	0.27	0.30	0.33	0.22	0.46	0.50	0.67	0.70	0.55	0.47	0.43	0.37	0.36	0.35	0.33	0.29	0.30	0.32	0.26	0.24	0.55	0.34	0.37	0.32
Diluted
-1.55	-0.11	-0.28	-0.06	0.09	0.03	-0.01	0.20	0.13	0.43	1.12	0.18	0.04	0.09	-0.02	0.21	0.47	0.50	0.42	0.26	0.29	0.32	0.21	0.43	0.48	0.66	0.68	0.53	0.46	0.42	0.36	0.34	0.34	0.33	0.29	0.29	0.31	0.26	0.24	0.54	0.33	0.36	0.31
Weighted average shares outstanding:
Basic
74,500	74,400	73,700	73,400	73,300	74,200	73,000	70,100	69,800	69,300	68,600	68,200	68,100	68,200	68,800	69,900	70,900	70,500	68,700	69,200	70,700	72,500	72,800	74,334	73,821	75,070	79,575	79,961	80,375	81,692	81,572	84,290	84,403	84,498	85,241	86,179	88,206	91,528	93,263	96,259	96,853	96,270	95,970
Diluted
74,500	74,400	73,700	74,800	74,900	76,500	73,000	72,900	72,400	71,900	70,400	68,900	68,300	68,300	68,800	74,200	73,500	73,800	72,100	72,600	73,900	75,400	76,100	77,803	76,374	76,825	81,798	82,612	82,434	84,240	83,914	86,130	86,462	86,231	87,037	88,308	90,127	93,647	94,734	98,016	99,674	99,426	99,492
Net income
-115,200	-8,300	-20,600	-4,200	6,900	2,600	-700	14,500	9,100	30,900	78,800	12,300	2,800	6,100	-1,200	-	-	-	-	-	-	-	-	-	36,770	50,360	55,465	-	37,892	35,036	30,136	29,141	29,615	28,296	25,099	26,041	27,940	24,191	22,538	53,251	33,251	35,359	30,442
Comprehensive income:
Unrealized gain (loss) on available-for-sale securities, net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45	253	285	-	259	-70	83	-	63	-60	-	-	-	-	-	-	-	-	-
Change in foreign currency translation adjustment, net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-672	-112	504	-	-497	-280	208	-	91	-80	-	-	-	-	-	-	-	-	-
Comprehensive income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36,143	50,501	56,254	-	37,654	34,686	30,427	29,078	29,769	28,156	24,835	-	-	-	-	-	-	-	-
Molecular Diagnostic Testing [Member]
Total revenue
150,500	181,100	172,000	196,900	200,500	203,000	189,000	180,600	169,300	173,100	167,400	187,000	183,000	184,100	165,100	160,500	177,400	182,600	171,900	178,800	173,000	179,200	164,500	182,864	176,191	196,158	192,987	166,097	148,384	140,651	127,268	127,499	123,312	117,610	103,969	105,374	102,374	100,440	91,858	-	-	-	-
Total costs and expenses
43,100	41,000	41,200	41,600	40,300	44,000	42,300	38,000	36,800	37,700	36,200	35,600	37,900	37,400	34,300	34,200	33,600	34,100	30,900	31,900	33,000	35,100	32,800	28,258	23,648	22,755	21,439	18,440	16,462	15,566	13,932	13,872	13,465	12,815	11,300	11,447	11,133	12,046	11,011	11,261	10,880	11,083	11,062
Pharmaceutical and Clinical Services [Member]
Total revenue
13,500	14,000	14,300	18,500	16,100	13,800	13,300	13,300	13,800	14,800	11,400	12,600	11,700	12,600	12,400	12,700	13,100	10,700	11,600	11,100	7,000	5,200	4,300	5,885	6,733	7,902	9,480	8,054	8,088	8,489	6,169	5,466	6,465	5,201	6,483	-	-	-	-	-	-	-	-
Total costs and expenses
7,000	8,600	8,500	9,000	8,300	8,100	7,400	7,700	7,300	6,700	6,800	6,900	6,400	7,000	5,700	5,800	6,600	6,500	5,600	6,400	3,300	2,800	2,100	2,721	2,961	3,376	4,042	3,715	3,872	4,318	3,395	3,081	3,763	3,302	3,061	-	-	-	-	-	-	-	-